Table 1.
SUC | CUC | ||
---|---|---|---|
Variables | N = 38 | N = 287 | P Value (Pearson χ2, Fischer exact test, t test) |
Gender | n, % | n, % | |
Male | 28 (74) | 220 (77) | .686 |
Female | 10 (26) | 67 (23) | |
Median age (y, IQR) | 70 (60–76) | 67 (60–76) | .987 |
Stage at diagnosis | |||
cT2 | 20 (53) | 162 (56) | .656 |
cT3/4 | 18 (47) | 125 (44) | |
Nodal disease (imaging) | 7 (18) | 25 (9) | .078 |
CIS+ (TURBT) | 11 (29) | 61 (21) | .289 |
LVI+ (TURBT) | 4 (11) | 36 (13) | .802 |
Surgical pathology | |||
pT0N0 | 3 (8) | 71 (25) | .015 |
pTa/T1/CIS | 3 (8) | 72 (25) | <.001 |
pT2 | 7 (18) | 45 (16) | .665 |
pT3/T4 | 25 (66) | 99 (35) | <.001 |
pTanyN+ | 10 (26) | 58 (20) | .384 |
Positive margins | 2 (5) | 17 (6) | 1.000 |
CIS+ | 9 (24) | 61 (21) | .732 |
LVI+ | 8 (21) | 55 (19) | .782 |
Recurrence rate | 17 (45) | 81 (28) | .041 |
Neoadjuvant CT | 17 (45) | 162 (56) | .173 |
pCR (ypT0N0) | 1/17 (6) | 56/162 (35) | 0.016 |
Abbreviations: CUC = conventional urothelial carcinoma; cT = clinical tumor stage; CT = chemotherapy; CIS = carcinoma in situ; IQR = interquartile range; LVI = lymphovascular invasion; pT = pathologic tumor stage; SUC = sarcomatoid urothelial carcinoma.